DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study (Q34109066)

31 July 2017

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study (English)

1 reference

31 July 2017

0 references

0 references

Kazufumi Nakamura

1

1 reference

31 July 2017

Hiroki Oe

2

1 reference

31 July 2017

Hajime Kihara

3

1 reference

31 July 2017

Kenei Shimada

4

1 reference

31 July 2017

Shota Fukuda

5

1 reference

31 July 2017

Kyoko Watanabe

6

1 reference

31 July 2017

Tsutomu Takagi

7

1 reference

31 July 2017

Kei Yunoki

8

1 reference

31 July 2017

Toru Miyoshi

9

1 reference

31 July 2017

Kumiko Hirata

10

1 reference

31 July 2017

Junichi Yoshikawa

11

1 reference

31 July 2017

Hiroshi Ito

12

1 reference

31 July 2017

language of work or name

English

0 references

publication date

30 July 2014

1 reference

Cardiovascular Diabetology

31 July 2017

1 reference

31 July 2017

13

1 reference

31 July 2017

110

1 reference

Creative Commons Attribution 2.0 Generic

31 July 2017

start time

30 July 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12933-014-0110-2

0 references

cites work

Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Effects of sitagliptin beyond glycemic control: focus on quality of life

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

CD34-positive stem cells: in the treatment of heart and vascular disease in human beings

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Revised equations for estimated GFR from serum creatinine in Japan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Effect of acarbose on vascular disease in patients with abnormal glucose tolerance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Impact of ageing on the measurement of endothelium-dependent vasodilation.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Acarbose: an alpha-glucosidase inhibitor.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149239

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12933-014-0110-2

Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25074318

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25074318

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S12933-014-0110-2

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference